About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Role of Direct-acting Antiviral Drugs in the Treatment of HCV Infections

by Anjali Aryamvally on April 15, 2018 at 7:34 PM
Font : A-A+

Role of Direct-acting Antiviral Drugs in the Treatment of HCV Infections

The percentage of liver transplants performed as a result of hepatitis C virus (HCV) infection in Europe has decreased in half since the availability of direct-acting antiviral (DAA) drugs, shows new study. The post-transplant survival rates among those with HCV infection have reached an all-time high, according to a study presented at The International Liver Congress 2018 in Paris, France.

Advertisement


'Direct-acting antiviral drugs have revolutionized the treatment of HCV-infected individuals - even those with advanced liver disease', explained Dr Giovanni Perricone from the ASST Great Metropolitan Hospital Niguarda in Milan, Italy, who presented the study findings today. 'Unlike the older HCV treatment regimens involving ribavirin and pegylated interferon, these newer agents are highly effective and well tolerated across genotypes, and we have shown previously that the remarkable clinical improvements that can be achieved using these agents can lead to the delisting of some individuals waiting for liver transplantation '.

In the latest research conducted by Dr Perricone and colleagues, data from the European Liver Transplant Registry from between January 2007 and June 2017 were reviewed, involving a total of 36,382 adults who underwent liver transplantation as a result of HCV, HBV, alcoholic liver disease or non-alcoholic steatohepatitis (NASH). To assess the impact of DAAs on liver transplantation rates, data were analyzed in separate treatment eras: the interferon (IFN) era from 2007 to 2010, the protease inhibitor (PI) era from 2011 to 2013, and the second-generation DAA era from 2014 to June 2017.
Advertisement

The percentage of liver transplants conducted as a result of HCV infection decreased from 22.8% during the IFN era to 10.6% during the DAA era. In contrast, the percentage of transplants conducted as a result of NASH increased from 1.1% to 6.2%. Within the DAA era, the percentage of liver transplants due to HCV decreased from 21.1% during the first half of 2014 to 10.6% during the first half of 2017.

According to Dr Perricone, the decreased requirement for liver transplantation during the DAA era was more pronounced in patients with HCV related to decompensated liver disease (-68.8%) than in those with HCV-related hepatocellular carcinoma (-34.0%). The 3-year survival of liver transplant recipients with HCV infection has also improved from 65.1% in the IFN era to 76.9% in the DAA era - a survival rate that is now comparable to that of patients with HBV infection (78.0%) (p=0.38).

'Our study provides clear evidence that DAAs are changing the epidemiology of liver transplantation, at least in countries like Italy where the prevalence of HCV infection is high',3 said Dr Perricone. 'We anticipate that rates of HCV-related transplantation will continue to decline as more patients gain access to these highly effective treatments'.

'For the first time in many years, we have also seen improved survival in liver transplant recipients with HCV infection, and this can be attributed directly to the availability of DAA drugs'.

'These are very important data that emphasize the effectiveness of DAA therapies against HCV', said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. 'These data are important, especially as a recent Cochrane report has concluded that there is not sufficient evidence to understand how sustained virological response affects long-term clinical outcomes'.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Drugs Banned in India Hepatitis C Postherpetic Neuralgia HCV Drug Treatment - New Frontiers 

Recommended Reading
Antiviral Drugs for the Prevention and Treatment of Influenza
Use of neuraminidase inhibitors in the treatment and prevention of influenza can only be prescribed ...
New Class of Antiviral Drugs Could Come from DNA 'Scrunching'
Evidence of DNA 'scrunching' may one day lead to a new class of drugs against viruses, suggested a ....
Use of Antiviral Drugs in Retrovirus-Infected Cats
Retrovirus-infected cats need special management and care, and provided they receive this can live ....
Research Sheds Light on Broad-Spectrum Antiviral Drugs for Common Cold and Other Infections
Progress has been made by scientists in the search for the first broad-spectrum drugs to combat ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
HCV Drug Treatment - New Frontiers
Hepatitis C is an inflammation of the liver caused by a virus. It is primarily spread through blood ...
Hepatitis C
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C ......
Postherpetic Neuralgia
Postherpetic neuralgia is a type of nerve pain that occurs following shingles or herpes zoster....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use